drugset / Trial / NCT06308588
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
NaSingle-groupOpen-labelTreatment
Summary
To learn if the combination of blinatumomab and asciminib can help to control Ph+ ALL.
Timeline
- Start
- 2024-08-05
- Primary completion
- 2027-05-01
- Completion
- 2029-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Asciminib | Unknown | — | Oral |
| Subject | Blinatumomab | Monoclonal antibody | — | Other |